Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
boston blog main
boston top stories
national top stories
san francisco blog main
san francisco top stories
boston
deals
new york blog main
san francisco
startups
abcellera
alphabet
antibodies
azacitidine
beta-thalassemia
broad institute of harvard and mit
brook byers
cancer
cancer diagnostics
charles chu
clinical trials
codiak biosciences
coronavirus
covid-19
crispr
crispr cas14
cutaneous t-cell lymphoma
dacogen
decheng capital
decitabine
diagnostic
dna
drug discovery
eli lilly
epigenetics
epizyme
exosome
What
based
5
×
medicines
biosciences
biotech
developing
new
screening
tests
tiny
abcellera
abcellera’s
aims
announced
antibodies
antibody
approach
area
available
bay
begin
big
bio
biologics
biopsy
bio’s
blood
brings
bubbles
buildout
called
cancer
cas
cells
cheaper
class
clinical
close
codiak
company
coronavirus
Language
unset
5
×
Current search:
xconomy.com
×
based
×
unset
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
